25 results about "Long acting" patented technology

Provided herein are variant α4β7 integrin antibodies and methods of use.

The invention discloses a long-acting pellet suitable for gastric absorption and a preparation method of the long-acting pellet. The long-acting pellet is prepared from the following components in parts by mass: 0.01-1 part of a medicine, 1-2.5 parts of a filler, 0.2-0.7 part of a modified pore-foaming agent mixture, 1-2.5 parts of an improved adhesive mixture and 0.1-0.7 part of an improved sonokinetic response agent. Wherein the modified pore-foaming agent mixture is prepared from a modified pore-foaming agent and glycosylated saponin, the modified pore-foaming agent is prepared by mixing a pore-foaming agent and seleno-amino acid according to a mass ratio of 4: 1, the improved adhesive is mixed with the adhesive through BHP-SH, and ionic crosslinking is performed by using CaCl2 to form a covalent ion dual network, so that the stomach adhesiveness is enhanced; the sonokinetic response agent is improved by the coated poria cocos extract, and the long-acting pellet is prepared by adopting a wet granulation method or a fluidized bed method, has the characteristics of slow release, long acting, targeted stomach absorption and responsive drug release, and is suitable for treating stomach diseases such as gastritis.

The invention relates to a polypeptide oligonucleotide conjugate with a structure as shown in a formula (I) or (II) or a pharmaceutically acceptable salt or a stereoisomer thereof, and an application of the polypeptide oligonucleotide conjugate or the pharmaceutically acceptable salt or the stereoisomer thereof. The polypeptide oligonucleotide conjugate can be used for inhibiting expression of one or more target genes of central nervous system tissue cells, and has the advantages of good in-vivo effect, long action time and good safety.

The present application relates to the technical field of HPV repair, in particular to a long-acting sustained-release device combination for treating female vaginal HPV infection and a use method thereof, which provides a safe, low-irritation and convenient-to-use drug delivery mode, and comprises a vaginal drug delivery device A and a device B used in cooperation with each other, the magnetic therapy of the vaginal drug delivery device A can promote capillary dilation and improve microcirculation, the IgY in the drug sustained-release layer of the vaginal drug delivery device A can be stably kept in the gel at a high titer, the alginate sulfate-carboxymethyl chitosan composite microemulsion makes the drug more easily gathered at the infection site, the magnetic therapy and the sustained-release drug interact with each other, promote the absorption and dissipation of inflammation, and produce a good repair environment, the functional powder dressing of the subsequent vaginal drug delivery device B is convenient for mild absorption of the exudate on the surface of the vagina after the magnetic therapy and the drug sustained-release treatment without causing discomfort, and the functional powder dressing releases various ions at a certain rate, further repairing damaged cells and tissues.

The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formulations. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Provided herein are variant α4β7 integrin antibodies and methods of use.

The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence.The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments.The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Disclosed herein are polymeric nanoparticles containing peptides, which provide low burst release and sustained, delivery of the peptides, and pharmaceutical compositions thereof. The polymeric nanoparticles contain a peptide encapsulated or dispersed therein. The nanoparticles can provide sustained release of the peptide, for example, less than 20% of the peptide is released initially (at time 0 hour) following placement into a phosphate buffered saline at pH 7.4 at 37° C. and room pressure. Methods for micronizing a peptide and for preparing polymeric nanoparticles containing solid, micronized peptides are also disclosed. The preparation methods use miscible solvent and non-solvent pairs in phase inversion nanoencapsulation processes. The Gibbs energy of mixing (ΔGMix) between the solvent and non-solvent can be tailored to achieve desired particle size, encapsulation efficiency, and release profile.

Described herein are compositions, devices, and methods useful for treating (reversing) and / or preventing fentanyl overdose resulting in respiratory failure or airway obstruction (FIVCC). Compositions are provided that include optimized amounts and / or ratios of two active ingredients, including: an alpha 2 adrenergic receptor agonist (e.g., lofexidine, dexmedetomidine, clonidine) and a short acting mu opioid receptor antagonist (e.g., naloxone); an alpha 2 adrenergic receptor agonist and a long acting mu opioid receptor antagonist (nalmefene); and an alpha 2 adrenergic receptor agonist and a fentanyl opioid analgesic. Methods and devices for concurrent delivery of combined active ingredients are also provided.

The present disclosure relates to a dose initiation method of performing an aripiprazole treatment on a patient in need thereof, the method comprising administering two separate aripiprazole injections and a single oral aripiprazole on the first day of aripiprazole treatment wherein the first aripiprazole injection is a long acting injection (LAI) and the second aripiprazole injection is a single dose oral aripiprazole injection. And the second injection of aripiprazole is an injection once a month (AOM). Maintaining administration is performed with a maintained dose of the LAI about two months after the first day of the aripiprazole treatment. The method is suitable for application parts of deltoid muscles and gluteus muscles.

The present invention relates to an injectable delivery system for long-acting administration of drugs. The present invention includes compounds formed at least in part from peptidomimetic molecules. The compound is configured to link one or more drug molecules, and is further configured to release the one or more drug molecules under physiological conditions. A solution of the compound forms a hydrogel in response to an endogenous enzyme of a human or animal. A solution of the compound can be applied to the skin where it forms a hydrogel upon application, and any drug attached to the compound will then be gradually released.

The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) dual agonist polypeptide which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.

Provided herein are anti-avb6 integrin engineered polypeptides, fusion proteins thereof with an Fc domain, and pharmaceutically acceptable compositions comprising the same. The anti-avb6 integrin engineered polypeptides of the present technology selectively bind the avb6 integrin with low-nanomolar or picomolar binding activity.

The invention discloses a ceftiofur injection and a preparation process thereof, and belongs to the technical field of veterinary drug preparations. The ceftiofur injection is prepared from the following components: ceftiofur, hydrogenated castor oil, poloxamer, polyethylene glycol, sesame oil and caprylic capric triglyceride. The invention provides the ceftiofur injection which has fast-acting property, ultra-long timeliness and stable product quality. The problem of both quick acting and long acting is successfully solved; the quick-acting and long-acting characteristics of the preparation are balanced; and when in use, the injection is easy to extract and push, small in irritation to an injection part and high in bioavailability, so that not only are the compliance and the treatment effect of animals remarkably improved, but also the administration frequency is reduced and the treatment cost is reduced due to the unique quick-acting and long-acting characteristics of the injection.

Methods of preventing the side effects of antibody drug conjugate therapies and other long acting emetogenic therapies such as nausea and vomiting, particularly in the long-delayed phase (i.e. > 120 hours).

The present application belongs to the technical field of cattle breeding, and provides a method for promoting the development of bovine follicles by injecting long-acting recombinant follicle-stimulating hormone into the urogenital mesoderm. The method comprises injecting an effective dose of long-acting recombinant follicle-stimulating hormone into the urogenital mesoderm of a cow. By injecting long-acting recombinant follicle-stimulating hormone (LArF) into the urogenital mesoderm, slow, continuous and direct action can be achieved, while off-target effects and pain are minimized. In addition, by using the minimum injection volume, the risk associated with the injection operation can be further reduced. In addition, the urogenital mesoderm injection scheme has the advantages of simpler operation, higher safety, less stress, more efficient process and lower cost under the premise of ensuring the follicle size and oocyte number required for oocyte collection.

The present invention relates to methods and compositions for treating and / or inhibiting the development or progression of a disease or disorder caused by or associated with herpesvirus infection. Specifically, provided are: an oral high bioavailability and long acting pharmaceutical composition comprising Compound 1; a preparation method thereof; and the use of said pharmaceutical composition as a medicament and for the treatment of diseases or disorders caused by or associated with herpes viruses.

The present disclosure provides a GLP1 analogue and a GLP1 / GIP receptor co-agonist analogue, a fusion protein comprising the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue, and methods of use thereof. In various embodiments, the fusion protein comprises the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue, which is fused to a protective antibody, or further fused to a stabilizing domain. In one embodiment, the fusion protein can be used to treat or ameliorate symptoms or indications of diseases such as obesity and diabetes.

Methods of preventing the side effects of antibody drug conjugate therapies and other long acting emetogenic therapies such as nausea and vomiting, particularly in the long-delayed phase (i.e. >120 hours).

The invention provides collagen as well as a preparation method and a preparation thereof. The method comprises the following steps: dissolving a collagen extract in acid, sequentially carrying out 450 kDa-550 kDa membrane ultrafiltration and two times of 250 kDa-350 kDa membrane concentration treatment, and further carrying out crosslinking and sterilization on the prepared collagen concentrated solution to prepare the collagen. According to the method, impurities and immune sources in the collagen extract are removed through ultrafiltration and two times of concentration treatment, purification of the collagen extract is achieved, the molecular weight and distribution of collagen are regulated and controlled, and therefore the crosslinking degree and crosslinking stability of the collagen are regulated and controlled. The collagen prepared by the invention has excellent stability and biodegradability resistance, can be widely applied to the fields of medical instruments, medical cosmetology and the like, and has the advantage of long acting time.

The present invention relates to a pharmaceutical composition use as a long acting injectable in the treatment of and / or prevention of pulmonary hypertension. The pharmaceutical composition is administered at a time interval of 1 to 8 weeks, and comprises calcium;{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate or hydrate or solvate thereof in the form of an aqueous suspension. In particular, such suspension is an aqueous suspension comprising microparticles of calcium;{4-[(5,6- diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate or hydrate or solvate thereof; and further comprising a surfactant and / or wetting agent, a buffer and / or pH adjusting agent; and a pharmaceutically acceptable aqueous carrier.

The present invention relates to an ultra-long-acting platform for improving the half-life of an active molecule of a drug, the platform comprising an immunoglobulin Fc and a long-chain fatty acid chain. The present invention also relates to the preparation of the conjugate platform, a composition comprising the conjugate, and its therapeutic application. The present invention particularly relates to a conjugate molecule having the structure "active molecule-Fc-Cn", where the active molecule is selected from any molecule beneficial to an organism, Fc is immunoglobulin IgG Fc, and Cn is C. 14-24 The modified moiety comprises a fatty acid chain. The present invention further relates to the preparation of the conjugate molecule, compositions comprising the conjugate, and therapeutic applications thereof.

The invention provides a sustained-release microsphere patch containing growth factors and application of the sustained-release microsphere patch in repairing pressure sore wounds. The patch comprises a backing layer, a drug-loaded microsphere layer and a protective stripping liner, the drug-loaded microsphere layer is composed of sustained-release microspheres dispersed in a medical adhesion matrix, the sustained-release microspheres are formed by wrapping basic fibroblast growth factors and epidermal growth factors with carboxyl-terminated PLGA, the mass ratio of the basic fibroblast growth factors to the epidermal growth factors is 1: (2-3), the sustained-release microspheres with the high encapsulation efficiency are prepared through a W / O / W multiple emulsion method, and controllable release of the growth factors is achieved; and chitosan modified nano-silver is added to enhance the antibacterial property, so that the patch can remarkably promote granulation tissue growth and epithelium repair, is effectively used for II-IV stage pressure sore wound treatment, and has the advantages of slow release, long acting, infection reduction and convenience in use.

The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.